Promising Efficacy of AT101 CAR-T for Blood Cancer
SEOUL, South Korea, April 17, 2023 /PRNewswire/ -- AbClon, a South Korean biotech firm, presented non-clinical and phase 1 interim results of its ...
Source: businessinsider.com
Stay updated with breaking news from Professor Dok. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SEOUL, South Korea, April 17, 2023 /PRNewswire/ -- AbClon, a South Korean biotech firm, presented non-clinical and phase 1 interim results of its ...